The Antimicrobial Commercialization Paradox: Building a Market While Preserving Efficacy

The Antimicrobial Commercialization Paradox: Building a Market While Preserving Efficacy
Author: David Alvaro, PhD
Published date: 16 November 2026
Category:
Economics & Funding Human Health Innovation
Share

For developers of new antibiotics and antifungals, a successful launch presents an unusual challenge: establishing a market for a product whose use must remain clinically appropriate and carefully managed. A therapy can address a serious unmet medical need, demonstrate clinical value, and secure regulatory approval, yet still encounter obstacles that prevent appropriate patients from receiving it. Meanwhile, efforts to preserve antimicrobial effectiveness can constrain the utilization on which conventional pharmaceutical revenue models depend.

These pressures shape antimicrobial commercialization. Hospitals may restrict prescribing to specific clinical circumstances, require infectious disease approval, or reserve certain therapies for patients with limited alternatives. Diagnostic capabilities influence which patients can be identified as candidates for treatment, while formulary decisions, procurement procedures, and reimbursement arrangements determine whether the product is accessible when needed. The importance of each factor varies across antibacterial and antifungal therapies, indications, and treatment settings.

Such restrictions are often deliberate components of antimicrobial stewardship. The Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend preauthorization and prospective audit and feedback as core approaches to improving antibiotic prescribing.1 These interventions provide institutional mechanisms for guiding treatment decisions and limiting inappropriate use.

For emerging biotechnology companies, commercialization planning must therefore begin well before launch. Decisions about clinical indications, evidence generation, diagnostic support, market access, and partnerships influence the eventual opportunity. Investors must evaluate whether projected revenues reflect the realities of appropriate prescribing and whether the company can support the infrastructure necessary to make treatment available.

Defining the Market: From Clinical Need to Realizable Demand

The burden of an infection provides an important starting point for estimating commercial opportunity, but it does not establish how many patients will ultimately receive a new antimicrobial. The population represented in epidemiological estimates may differ substantially from the serviceable market a manufacturer can realistically reach.

Estimating that market requires following patients through several successive considerations: whether they meet the product’s clinical criteria, whether appropriate diagnostic testing identifies them, whether their treating institution has access to the therapy, whether prescribing authorization is required, and whether treatment can be delivered within the necessary timeframe.

Each consideration can narrow the opportunity represented in a revenue forecast. Patients may be clinically eligible but receive care at hospitals that do not routinely stock the drug. Others may be treated at institutions with access but encounter diagnostic or authorization procedures that influence treatment selection. Their commercial significance depends on their frequency and whether launch preparation can address them.

Cefiderocol, an antibiotic used to treat certain serious Gram-negative bacterial infections, illustrates the institutional dimension of access. The U.S. Department of Veterans Affairs lists the product as requiring local prior authorization, with prescribing restricted to infectious disease, antimicrobial stewardship, or other authorized providers.2 At Zuckerberg San Francisco General Hospital, cefiderocol is listed as non-formulary, while the hospital’s broader restricted-antimicrobial workflow requires approval from designated infectious disease personnel for restricted therapies.3 These policies demonstrate how institutions can maintain stewardship oversight while establishing procedures for appropriate treatment.

These policies shape the market manufacturers can realistically reach. A therapy intended for use in resistant infections may reach a relatively concentrated group of prescribing specialists, pharmacists, and institutions. The relevant market may therefore be better understood through the treatment settings where appropriate patients receive care than through the overall number of physicians treating the disease.

This distinction influences forecasting and launch sequencing. Developers should evaluate how many institutions are likely to adopt the product, what diagnostic and clinical capabilities those institutions possess, and which operational requirements could affect utilization. A forecast based primarily on infection prevalence risks overstating demand if it assumes that all eligible patients are equally accessible. The serviceable market may also change as diagnostic availability, formulary decisions, and institutional treatment pathways evolve.

Investors can apply the same framework when assessing commercial projections. The most useful forecasts connect clinical eligibility with the practical conditions under which treatment occurs, distinguishing underlying medical need from the revenue opportunity a particular commercialization strategy can realistically address.

Regulatory Strategy and Commercial Messaging: Establishing the Product’s Clinical Role

A new antimicrobial’s commercial prospects depend partly on whether clinicians can determine when it is appropriate to use. For products targeting resistant infections, that often requires laboratory susceptibility testing supported by recognized interpretive criteria, alongside clinical evidence establishing the product’s approved role.

In the United States, the Food and Drug Administration (FDA) maintains a framework for recognizing antimicrobial susceptibility test interpretive criteria, commonly called breakpoints.4 These criteria help laboratories interpret whether a pathogen is susceptible to a particular antimicrobial. The FDA publishes recognized criteria online and provides mechanisms for updating them as scientific information evolves.

Regulatory evidence and diagnostic readiness directly influence clinical adoption. A product may demonstrate activity against important pathogens, but its use in practice also depends on whether laboratories can generate and interpret results that inform treatment selection. Planning for those capabilities can influence development priorities and the evidence needed to support the product’s intended clinical position.

Regulatory requirements also shape manufacturer communications. The FDA’s Office of Prescription Drug Promotion oversees prescription drug advertising and promotional labeling, while agency guidance addresses communications containing information that extends beyond, but remains consistent with, FDA-required labeling.5,6

These frameworks influence how companies communicate clinical differentiation, susceptibility findings, and appropriate treatment selection. Commercial teams must understand the product’s approved role, while medical affairs personnel address scientific questions about the supporting evidence. Both functions require coordination when discussing resistant pathogens or potential treatment applications.

For smaller developers preparing to license a product or establish a commercial partnership, clinical development programs should anticipate the evidence future commercial and medical teams will need to communicate the therapy’s value accurately. This may influence how developers plan supporting microbiological analyses, diagnostic resources, and evidence-generation activities alongside clinical endpoints, particularly when differentiation depends on a narrowly defined population or pathogen profile.

The Last Mile: Making Appropriate Treatment Operationally Possible

Even when clinicians identify a suitable therapy, delivering treatment may require coordination among microbiology laboratories, infectious disease specialists, stewardship teams, pharmacists, purchasing departments, and reimbursement personnel. The operational pathway can be particularly complicated for specialized antimicrobials that institutions do not routinely stock or administer.

Diagnostic readiness is one component. Shionogi, which markets cefiderocol, provides information about available susceptibility testing methods and related laboratory resources.7 Such support addresses the practical need to generate information that clinicians can use when evaluating treatment options.

However, identifying the right treatment is only the beginning. Procurement and reimbursement arrangements can introduce additional obstacles after the clinical decision has been made.

Rezafungin, an echinocandin antifungal administered intravenously once weekly, provides an instructive example. Its dosing schedule can facilitate outpatient treatment, but accessing and administering the therapy requires appropriate institutional arrangements.

In a retrospective analysis, investigators participating in the international FungiScope registry examined rezafungin use in Germany, Italy, Spain, and the United States between January 2024 and June 2025. The study included 15 patients, 14 of whom had invasive candidiasis.8 Administrative and reimbursement barriers affected transitions to rezafungin in 71% of the patients with invasive candidiasis.

The researchers documented substantial differences among participating institutions. At one Italian center, patient-specific committee approval and a manufacturer purchase request delayed treatment initiation by at least two to three weeks. At a U.S. center where rezafungin was available through the hospital formulary, treatment could begin on the same day as an infectious disease recommendation, although outpatient administration was not available through that institution’s reported arrangement.

The study’s small, retrospective cohort does not establish how frequently such barriers occur across health systems. Its value lies in demonstrating how access arrangements can vary even among institutions treating patients who may benefit from the same therapy.

A separate case report by investigators at Massachusetts General Hospital, published in August 2026, describes the difficulties involved in maintaining prolonged rezafungin treatment across care settings.9 The patient received rezafungin for Candida sternal osteomyelitis, an application and treatment duration beyond those evaluated in the pivotal trials supporting its approval. The authors reported that their institution could procure the drug within one business day after infectious disease approval. However, the patient’s subsequent transition to outpatient treatment required insurance verification, prior authorization, patient assistance, and coordination with infusion providers. The report also describes financial challenges associated with a lack of prescription drug coverage and the need to identify an outpatient provider able to supply the therapy.

These experiences reveal an important distinction between physician demand and realizable access. A clinician’s decision to use an antimicrobial may initiate a series of institutional and financial processes that determine whether treatment proceeds. For products intended for both inpatient and outpatient use, those processes can differ considerably between care settings.

Commercial launch preparation should therefore examine the treatment pathway at prospective institutions rather than assuming that formulary adoption alone establishes readiness. Relevant considerations include pharmacy stocking, procurement timelines, prescribing authorization, reimbursement procedures, and the availability of appropriate administration services. Understanding these requirements can inform distribution, medical education, diagnostic support, and market access planning without weakening the safeguards that guide appropriate prescribing.

Designing Commercial Operations Around Stewardship

The need for selective prescribing raises questions about how manufacturers organize their commercial activities. Sales incentives, customer engagement, medical education, and licensing agreements influence how a therapy is positioned and supported after launch.

Shionogi offers a documented example of an alternative approach to commercial incentives. The company states that it does not tie sales staff compensation to antibacterial sales volume in markets where it directly commercializes its antibacterial products.10 Shionogi presents this policy as part of its commitment to appropriate use and antibiotic sustainability.

The Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark confirms that Shionogi separates sales incentives from volume targets, while noting that the company does not publicly specify the alternative qualitative targets used to evaluate employees.11 The available evidence establishes the policy but does not demonstrate whether it has changed prescribing behavior or resistance outcomes.

The policy also challenges conventional measures of commercial performance.

Revenue and institutional adoption remain important indicators of commercial viability. Stewardship alignment introduces additional considerations, including whether manufacturer communications support the approved clinical role and whether appropriate-use commitments are reflected in commercial activities. Operational performance concerns whether diagnostic resources, procurement arrangements, and treatment pathways allow eligible patients to receive therapy.

These dimensions require different measures, selected according to the product and its clinical role. Formulary adoption indicates institutional acceptance but does not establish appropriate prescribing. Similarly, educational activities may demonstrate implementation of a stewardship program without proving that the program has changed clinical behavior.

Smaller developers must also consider how such commitments will be maintained when commercialization depends on external partners. Licensing agreements can assign responsibilities for access, regulatory support, stewardship, and postmarket activities, providing a contractual foundation for execution across different markets.

The 2022 cefiderocol licensing agreement between Shionogi and the Global Antibiotic Research and Development Partnership (GARDP)  requires sublicensees to establish access plans with commercialization objectives and mechanisms for achieving access and antimicrobial stewardship goals.12 Shionogi retains approval rights over sublicensees and their access plans, while GARDP is responsible for monitoring and enforcing relevant obligations.

GARDP’s April 2025 request for information concerning commercial sublicenses for a generic version of cefiderocol provides further insight into the capabilities expected of partners.13 The requirements include country-specific commercial strategies, regulatory responsibilities, distribution and logistics planning, and experience commercializing injectable antibiotics. Selection criteria also address commitment to access and stewardship.

Although developed for a specific global access initiative, these arrangements demonstrate how commercialization partnerships can translate stewardship commitments into defined responsibilities and oversight mechanisms.

For a biotechnology company considering regional licensing or a broader commercialization partnership, financial terms and geographic reach provide only part of the picture. A partner’s ability to navigate institutional access, support appropriate-use education, manage distribution, and fulfill postmarket obligations may be equally important to the product’s long-term prospects.

Building a Sustainable Business When Utilization Is Constrained

The financial challenge facing antimicrobial developers begins with the relationship between appropriate utilization and revenue. A therapy may provide substantial clinical value for a relatively small population, particularly when stewardship programs reserve its use for defined circumstances. Yet the company must still recover development costs and support the activities required to supply the product.

A credible financial model must address how much revenue appropriate utilization can generate, what commercial infrastructure must be maintained regardless of sales volume, and whether alternative purchasing arrangements or partnerships can improve the economics.

Under a conventional sales model, revenue depends heavily on the number of units purchased. That relationship creates tension when the product’s intended clinical role supports limited utilization. Developers may face substantial requirements for medical affairs, distribution, market access, and postmarket evidence generation even when prescriptions remain relatively infrequent.

The United Kingdom’s antimicrobial subscription model provides an alternative approach. Developed through collaboration between the National Institute for Health and Care Excellence (NICE) and NHS England, the model compensates manufacturers through payments based on assessed value rather than the volume of antibiotics supplied.14,15 The initial pilot included cefiderocol and ceftazidime-avibactam.

The cefiderocol agreement illustrates the mechanics. NICE reports that the manufacturer receives quarterly payments that are not linked to the volume supplied to the National Health Service (NHS).16 Purchasing authorities acquire the product at a confidential invoice price, and NHS England deducts those purchasing costs from the quarterly payments. The agreement was established for an initial three-year period, with an option to extend its duration up to 10 years.

The contract also incorporates requirements concerning antimicrobial stewardship, resistance monitoring, manufacturing and environmental practices, and continuity of supply. The purchasing arrangement connects payment with obligations extending beyond delivering individual doses.

This structure recognizes that the value of maintaining access to an antimicrobial may not be adequately represented by the number of prescriptions generated. However, subscription arrangements are not universally available, and developers cannot assume that their products will qualify or receive commercially attractive terms.

Alternative purchasing arrangements can change how manufacturers are compensated for antimicrobial value. Developers also face decisions about which indications and markets justify the commercial investment required.

In October 2022, SCYNEXIS announced that it would redirect resources toward developing ibrexafungerp for severe hospital-based fungal infections, where the company anticipated higher long-term returns.17 It also announced plans to seek a commercialization partner for BREXAFEMME in vulvovaginal candidiasis and wind down its own promotional activities for that indication.

The decision reflected the company’s commercial priorities rather than a demonstrated resistance-prevention strategy. It illustrates how a developer may reassess the relative attractiveness of different indications, treatment settings, and commercialization models. Hospital-based products and therapies targeting broader outpatient populations can require different commercial capabilities, creating distinct implications for capital allocation and partnership strategy.

For emerging companies, the financial analysis should extend beyond projected peak sales. Commercial infrastructure, diagnostic support, medical affairs, distribution, regulatory compliance, and surveillance create ongoing costs that do not necessarily decline in proportion to utilization. Developers must determine which capabilities they can support internally and which should be provided through licensing or other partnerships.

A sustainable business model must reconcile expected revenue with the utilization patterns that appropriate clinical practice is likely to support. That alignment provides a stronger basis for decisions about financing, partnering, and resource allocation.

Postmarket Stewardship: Surveillance, Accountability, and Long-Term Value

Commercialization creates ongoing responsibilities to understand how an antimicrobial performs as clinical experience accumulates. Resistance surveillance can identify changing susceptibility patterns, inform treatment decisions, and support regulatory oversight. It also requires developers to plan for evidence generation after approval.

The European Medicines Agency’s (EMA’s) guideline on the evaluation of medicinal products for bacterial infections addresses expectations for marketing authorization holders to notify regulators of emerging resistance, changing resistance patterns, and newly identified resistance mechanisms.18 This regulatory guidance establishes a dimension of postmarket monitoring distinct from voluntary manufacturer stewardship programs.

Shionogi provides an example of manufacturer involvement in surveillance. According to the Access to Medicine Foundation’s 2026 assessment, the company participates in three national or multinational antimicrobial resistance surveillance programs: the Shionogi Cefiderocol Post-Marketing Japanese Surveillance Studies Programme, the Four Academic Societies Joint Antimicrobial Susceptibility Surveillance Programme, and the multinational SENTRY Antimicrobial Surveillance Programme.19

The Foundation identifies limitations in the transparency of some surveillance methods and underlying data. Although aggregated findings are available, the assessment highlights opportunities to improve the accessibility and completeness of information used to evaluate resistance patterns.

Stewardship accountability requires distinguishing activities from operational results and longer-term outcomes. A manufacturer may establish educational programs, support susceptibility testing, or participate in surveillance, but those activities do not independently demonstrate that resistance emergence has slowed. Establishing such an effect requires evidence capable of accounting for prescribing patterns, pathogen epidemiology, and other influences on resistance.

Developers can address this challenge by defining measurable objectives for their stewardship and access commitments. Implementation measures can establish whether planned activities occurred, while operational measures can assess whether institutions can obtain treatment and whether access pathways function as intended. Surveillance and clinical evidence can then contribute to understanding longer-term product performance without attributing outcomes to interventions that have not been shown to cause them.

Integrating Commercialization Into Antimicrobial Development

The commercial value of a new antimicrobial depends on more than its clinical differentiation or the size of the population it could treat. It also depends on whether the developer can establish a practical route to appropriate utilization and a business model capable of sustaining that access.

For emerging biotechnology companies, the necessary decisions begin during development. Indication selection influences the intended market, clinical evidence supports the product’s positioning, diagnostic capabilities shape patient identification, and commercialization agreements determine how access and stewardship commitments are executed.

Investors have an opportunity to evaluate these assumptions before approval, when they may still influence financing, development priorities, and partnership decisions. A compelling clinical profile establishes the potential value of a new antimicrobial. A credible commercialization strategy explains how that value can reach appropriate patients while supporting the investment needed to develop, supply, and sustain the therapy.

References

  1. 1. Barlam, Tamar F, et al. “Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.” Clinical Infectious Diseases. 62: e51–e77 (2016). https://doi.org/10.1093/cid/ciw118
  2. 2. “CEFIDEROCOL INJ,PWDR.” U.S. Department of Veterans Affairs, VA Formulary Advisor. Accessed 09 Nov. 2026. https://www.va.gov/formularyadvisor/drugs/4039175-CEFIDEROCOL-INJ-PWDR
  3. 3. “ZSFG Restricted Antimicrobials & Workflow.” University of California, San Francisco, Infectious Diseases Management Program. Updated 30 Aug. 2024. https://idmp.ucsf.edu/content/zsfg-restricted-antimicrobials-workflow
  4. 4. “FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.” U.S. Food and Drug Administration. Accessed 09 Nov. 2026. https://www.fda.gov/drugs/development-resources/fda-recognized-antimicrobial-susceptibility-test-interpretive-criteria
  5. 5. “The Office of Prescription Drug Promotion (OPDP).” U.S. Food and Drug Administration. Accessed 09 Nov. 2026. https://www.fda.gov/about-fda/cder-offices-and-divisions/office-prescription-drug-promotion-opdp
  6. 6. “Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers: Guidance for Industry.” U.S. Food and Drug Administration. 13 Jun. 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-product-communications-are-consistent-fda-required-labeling-questions-and-answers
  7. 7. “Fetroja® (cefiderocol): Diagnostic Testing.” Shionogi Inc. Accessed 09 Nov. 2026. https://www.fetroja.com/diagnostic-testing
  8. 8. Reinhold, Ilana, et al. “Rezafungin Utilisation in Real Life—FungiScope Results From Europe and the United States.” Mycoses. 68: e70114 (2025). https://doi.org/10.1111/myc.70114
  9. 9. Li, Jian Mei, Jacqueline E Clark, and Tiffany Wu. “Long-Term Use of Rezafungin: A Case Report and Insights Into Real-World Access.” Transplant Infectious Disease. Early View: e70262 (2026). https://doi.org/10.1111/tid.70262
  10. 10. “Promote Proper Use of Medicines.” Shionogi & Co., Ltd. Accessed 09 Nov. 2026. https://www.shionogi.com/global/en/sustainability/improve-access-to-healthcare/proper-use.html
  11. 11. “Shionogi & Co, Ltd.” Access to Medicine Foundation. 2026 Antimicrobial Resistance Benchmark. 2026. https://accesstomedicinefoundation.org/company/shionogi-co-ltd/amrb
  12. 12. “Shionogi–GARDP, Cefiderocol License Agreement.” Global Health Innovation Alliance Accelerator. Agreement effective 15 Jun. 2022. https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-2/
  13. 13. “Request for Information for the Award of Commercial Sublicense Agreements for a Generic Version of Cefiderocol.” Global Antibiotic Research and Development Partnership. 16 Apr. 2025. https://gardp.org/rfp/request-for-information-for-the-award-of-commercial-sublicense-agreements-for-a-generic-version-of-cefiderocol/
  14. 14. “Antimicrobial Products Subscription Model: Guidance on Commercial Arrangements.” NHS England. 8 May 2024. https://www.england.nhs.uk/long-read/antimicrobial-products-subscription-model-guidance-on-commercial-arrangements/
  15. 15. “A New Model for Evaluating and Purchasing Antimicrobials in the UK.” National Institute for Health and Care Excellence. Accessed 09 Nov. 2026. https://www.nice.org.uk/what-nice-does/life-sciences-how-to-get-your-product-to-market/a-new-model-for-evaluating-and-purchasing-antimicrobials-in-the-uk
  16. 16. “Cefiderocol for Treating Severe Drug-Resistant Gram-Negative Bacterial Infections.” National Institute for Health and Care Excellence. 17 Aug. 2022. https://www.nice.org.uk/guidance/amr2/resources/cefiderocol-for-treating-severe-drugresistant-gramnegative-bacterial-infections-pdf-833166752965
  17. 17. “SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal.” SCYNEXIS, Inc. 20 Oct. 2022. https://ir.scynexis.com/news-events/press-releases/detail/305/scynexis-provides-corporate-commercial-and-rd-strategy
  18. 18. “Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections – Revision 3.” European Medicines Agency. 24 May 2022. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf
  19. 19. “Shionogi & Co, Ltd.” Access to Medicine Foundation. 2026 Antimicrobial Resistance Benchmark. 2026. https://accesstomedicinefoundation.org/company/shionogi-co-ltd/amrb

Subscribe to
disAMR Matters

Receive newly released thought leadership articles and news in your inbox twice a month.

Name(Required)